Prescription digital therapeutics are software programs that physicians prescribe as a form of treatment. They can help patients manage serious conditions ranging from opioid addiction to asthma to sleep disorders.
During the COVID-19 crisis, managed care professionals are facing unique challenges to deliver patient care. This resource center is designed to aggregate timely information for AMCP members and stakeholders.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
To engage in meaningful dialogue and identify concrete actions toward addressing health disparities, it is imperative to have a common language that promotes understanding. To that end, AMCP has compiled a glossary of terms that will be useful for managed care pharmacists, other health care professionals, and stakeholders.
AMCP is pleased to be recognized by the Office of Disease Prevention and Health Promotion within the U.S. Department of Health and Human Services as a Healthy People 2030 Champion.
